Storage/Stability
Jynarque: Store at 20?C to 25?C (68?F to 77?F); excursions permitted between 15?C and 30?C (59?F and 86?F).
Adverse Reactions
>10%:
Central nervous system: Fatigue (14%), dizziness (11%)
Endocrine & metabolic: Increased thirst (12% to 64%)
Gastrointestinal: Nausea (21%), xerostomia (7% to 16%), diarrhea (13%)
Renal: Polyuria (including pollakiuria, 4% to 70%)
1% to 10%:
Cardiovascular: Palpitations (4%), cerebrovascular accident (<2%), deep vein thrombosis (<2%), intracardiac thrombus (<2%), pulmonary embolism (<2%), ventricular fibrillation (<2%)
Dermatologic: Xeroderma (5%), skin rash (4%)
Endocrine & metabolic: Increased serum sodium (2% to 7%), hyperglycemia (6%), hyperuricemia (4%), hypernatremia (?4%), dehydration (2% to 3%), hypovolemia (2%), diabetic ketoacidosis (<2%)
Gastrointestinal: Gastrointestinal hemorrhage (cirrhosis patients, 10%), dyspepsia (8%), constipation (7%), decreased appetite (7%), abdominal distention (5%), anorexia (4%), ischemic colitis (<2%)
Genitourinary: Urethral bleeding (<2%), vaginal hemorrhage (<2%)
Hematologic & oncologic: Disseminated intravascular coagulation (<2%), prolonged prothrombin time (<2%)
Hepatic: Increased serum alanine aminotransferase (5%)
Neuromuscular & skeletal: Asthenia (9%), rhabdomyolysis (<2%)
Respiratory: Respiratory failure (<2%)
Miscellaneous: Fever (4%)
<1%, postmarketing, and/or case reports: Anaphylactic shock, anaphylaxis, hepatic failure, hepatotoxicity, hyperkalemia, hypersensitivity reaction, increased serum bilirubin, osmotic demyelination syndrome, skin rash